Artelo Biosciences (NASDAQ:ARTL) Given “Buy” Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a report published on Thursday,Benzinga reports. D. Boral Capital currently has a $6.00 price target on the stock.

Other equities research analysts have also issued research reports about the stock. LADENBURG THALM/SH SH upgraded shares of Artelo Biosciences to a “strong-buy” rating in a research note on Wednesday, December 25th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Artelo Biosciences in a research note on Monday, December 9th.

Artelo Biosciences Stock Down 3.1 %

Shares of ARTL stock opened at $1.06 on Thursday. The company has a 50 day moving average of $1.16 and a 200-day moving average of $1.16. Artelo Biosciences has a 12-month low of $0.91 and a 12-month high of $1.70. The firm has a market cap of $3.41 million, a P/E ratio of -0.37 and a beta of 1.25.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.